. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Feb 17;9(6):2517–2519.e2. doi: 10.1016/j.jaip.2021.01.045

Table 1.

Treatment Course

Treatment	Symptom response	EGD outcome (EREFS)	Eosinophil counts, proximal (eos/hpf)	Eosinophil counts, distal (eos/hpf)	Month of biopsy	Additional Notes
Omeprazole 20 mg twice daily x 12 weeks	No	Ex2, R1, E1, F1, S0 No dilation	62	21	March
2FED^* (dairy, wheat) x 8 weeks	No	Ex1, R2, E2, F1, S11 No dilation	90	45	August
4FED (dairy, wheat, egg, soy) x 6 weeks	No	Ex1, R2, E1, F1, S9 Dilation (Savary to 11mm)	180	10	October
6FED (dairy, wheat, egg, soy, peanuts/tree nuts, fish/shellfish) x 6 weeks	No	Ex1, R2, E1, F1, S9 Dilation (Savary to 12mm)	140	60	November
Oral viscous budesonide (OVB) 1 mg twice daily x 8 weeks	yes	Ex0, R1, E0, F0, S16 Dilation (Savary to 17mm)	0	0	March	OVB subsequently stopped due to family preference in order to start SCIT and observe the response
Off OVB and on multiallergen SCIT (build-up phase) x 3 months	yes	Ex1, R1, E1, F1, S16 Dilation (Savary to 17mm)	0	48	August
Multiallergen SCIT (maintenance phase) x 3 months	yes	Ex1, R0, E0, F1, S0	0	5	March
Multiallergen SCIT (maintenance phase) x 8 months	yes	Ex0, R0, E0, F0, S0	0	2	August	Remains asymptomatic on 18+ months of maintenance SCIT; follow-up EGD deferred due to covid-19 pandemic